“Our findings inform potential expected downstream consequences of interventions affecting lipid traits,” said Michael V. Holmes, MD, PhD, and his team. “And provide cautionary evidence that therapeutics that lower LDL-C and triglyceride levels may have dysglycemic effects.”
Holmes and the rest of the researchers performed genome-wide association studies using Mendelian randomization to look for “distinct associations” between different types of lipids and their relationship to higher or lower risk for coronary heart disease or type 2 diabetes. After receiving the contradicting results, they also considered that it could be the use of statin therapy to lower LDL-C levels that could be causing the risk of type 2 diabetes. Or perhaps, they thought, it could just be LDL-C medications in general. Regardless, there are still a lot of questions about what the results from this study mean.
“Large-scale genetic and clinical investigations are needed to clarify the effects of pharamcologic lowering of LDL-C and triglyceride levels to gauge dysglycemic associations,” the authors wrote.
Some scientists believe that the researchers’ methods, using mendelian randomization, are reliable for determining association of LDL-C and triglycerides with coronary artery disease, but not for associating LDL-C, HDL-C, and triglycerides with type 2 diabetes. “It seems that other approaches are required to further evaluate the causal relevance of each of these lipid fractions in association with type 2 diabetes,” said Danish Saleheen, MBBS, PhD, from the University of Pennsylvania, Philadelphia.
This study was recently published in the journal JAMA Cardiology.
Sources: NC Research Campus, American Heart Association, The JAMA Network Journals